<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Adalimumab (<z:chebi fb="36" ids="39048">ADA</z:chebi>) is a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) inhibitor, used for the treatment of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies have reported an increased risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> following exposure to TNF inhibitors, but little has been reported for patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> receiving TNF-inhibitor treatment </plain></SENT>
<SENT sid="2" pm="."><plain>We present a female patient with metastatic <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) who was treated with <z:chebi fb="36" ids="39048">ADA</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>A 54-year-old African American female with a past history of left-sided <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (BC) diagnosed at age 30 was initially treated with left-breast lumpectomy, axillary dissection, followed by chemotherapy and radiation therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Years after initial diagnosis, she developed recurrent, bilateral BC and had bilateral mastectomy </plain></SENT>
<SENT sid="5" pm="."><plain>Subsequent restaging computed tomography (CT) scan demonstrated distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> to the bone and lymph nodes </plain></SENT>
<SENT sid="6" pm="."><plain>Three years into her treatment of metastatic <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, she was diagnosed with UC by colonoscopy </plain></SENT>
<SENT sid="7" pm="."><plain>Her UC was not controlled for 5 mo with <z:chebi fb="0" ids="20551">5-aminosalicylates</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Subcutaneous <z:chebi fb="36" ids="39048">ADA</z:chebi> was started and resulted in dramatic improvement of UC </plain></SENT>
<SENT sid="9" pm="."><plain>Four months after starting <z:chebi fb="36" ids="39048">ADA</z:chebi>, along with ongoing chemotherapy, restaging CT scan showed resolution of the previously seen metastatic lymph nodes </plain></SENT>
<SENT sid="10" pm="."><plain>Bone scan and follow-up <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography/CT scans performed every 6 mo indicated the stability of healed metastatic <z:e sem="disease" ids="C0238792" disease_type="Disease or Syndrome" abbrv="">bone lesions</z:e> for the past 3 years on <z:chebi fb="36" ids="39048">ADA</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>While TNF-Î± inhibitors could theoretically promote further <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in patients with prior <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, this is the first report of a patient with metastatic <z:hpo ids='HP_0003002'>breast cancer</z:hpo> in whom the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> has remained stable for 3 years after <z:chebi fb="36" ids="39048">ADA</z:chebi> initiation for UC </plain></SENT>
</text></document>